Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer and has shown encouraging results in a recent pilot study. The study combined the HER2-targeting dendritic cell vaccines with standard chemotherapy, demonstrating both safety and positive response rates.
Read more https://www.sciencedaily.com/releases/2025/03/250318175019.htm